Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy adjustments.

IF 3.9 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Frontiers of Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-02 DOI:10.1007/s11684-024-1074-6
Zeyu Zhang, Yue Yan, Lina Zhao, Yizhou Bian, Ning Zhao, You Wu, Dahai Zhao, Zongjiu Zhang
{"title":"Trajectory of COVID-19 response and management strategy in China: scientific rationale driven strategy adjustments.","authors":"Zeyu Zhang, Yue Yan, Lina Zhao, Yizhou Bian, Ning Zhao, You Wu, Dahai Zhao, Zongjiu Zhang","doi":"10.1007/s11684-024-1074-6","DOIUrl":null,"url":null,"abstract":"<p><p>The pneumonia caused by novel coronavirus SARS-CoV-2 infection in early December 2019, which was later named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), rapidly spread across the world. China has made extraordinary efforts to this unprecedented pandemic, put its response and control at a very high level of infectious disease management (Category B but with measures for Category A), given top priority to the people and their lives, and balanced the pandemic control and socio-economic development. After more than three years' fighting against this disease, China downgraded the management of COVID-19 to Category B infectious disease on January 8, 2023 and the WHO declared the end of public health emergency on May 5, 2023. However, the ending of pandemic does not mean that the disease is no longer a health threat. Experiences against COVID-19 from China and the whole world should be learned to prepare well for the future public health emergencies. This article gives a systematic review of the trajectory of COVID-19 development in China, summarizes the critical policy arrangements and provides evidence for the adjustment during policy making process, so as to share experiences with international community and contribute to the global health for all humanity.</p>","PeriodicalId":12558,"journal":{"name":"Frontiers of Medicine","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11684-024-1074-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The pneumonia caused by novel coronavirus SARS-CoV-2 infection in early December 2019, which was later named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), rapidly spread across the world. China has made extraordinary efforts to this unprecedented pandemic, put its response and control at a very high level of infectious disease management (Category B but with measures for Category A), given top priority to the people and their lives, and balanced the pandemic control and socio-economic development. After more than three years' fighting against this disease, China downgraded the management of COVID-19 to Category B infectious disease on January 8, 2023 and the WHO declared the end of public health emergency on May 5, 2023. However, the ending of pandemic does not mean that the disease is no longer a health threat. Experiences against COVID-19 from China and the whole world should be learned to prepare well for the future public health emergencies. This article gives a systematic review of the trajectory of COVID-19 development in China, summarizes the critical policy arrangements and provides evidence for the adjustment during policy making process, so as to share experiences with international community and contribute to the global health for all humanity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国 COVID-19 应对和管理战略的轨迹:科学依据驱动战略调整。
2019年12月初,新型冠状病毒SARS-CoV-2感染引起的肺炎,后被世界卫生组织(WHO)命名为冠状病毒病2019(COVID-19),迅速波及全球。面对这场史无前例的疫情,中国做出了超乎寻常的努力,把应对和控制放在传染病管理的高度(乙类但有甲类措施),把人民群众生命安全放在首位,统筹兼顾疫情控制和社会经济发展。经过三年多的抗击,中国于 2023 年 1 月 8 日将 COVID-19 降为乙类传染病,世界卫生组织于 2023 年 5 月 5 日宣布结束突发公共卫生事件。然而,大流行的结束并不意味着该疾病不再威胁健康。中国和全世界应对 COVID-19 的经验值得借鉴,以便为未来的突发公共卫生事件做好准备。本文系统回顾了中国 COVID-19 的发展轨迹,总结了关键的政策安排,为政策制定过程中的调整提供依据,以期与国际社会分享经验,为全人类的全球健康做出贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers of Medicine
Frontiers of Medicine ONCOLOGYMEDICINE, RESEARCH & EXPERIMENTAL&-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
18.30
自引率
0.00%
发文量
800
期刊介绍: Frontiers of Medicine is an international general medical journal sponsored by the Ministry of Education of China. The journal is jointly published by the Higher Education Press and Springer. Since the first issue of 2010, this journal has been indexed in PubMed/MEDLINE. Frontiers of Medicine is dedicated to publishing original research and review articles on the latest advances in clinical and basic medicine with a focus on epidemiology, traditional Chinese medicine, translational research, healthcare, public health and health policies.
期刊最新文献
Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis. Epigenetic modifiers: catalytic or noncatalytic, that is the question. Intracellular checkpoints for NK cell cancer immunotherapy. PAK5-mediated PKM2 phosphorylation is critical for anaerobic glycolysis in endometriosis. Holistic Integrative Medicine Declaration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1